ReviewPharmaceutics2022
Transient Receptor Potential Channels: Important Players in Ocular Pain and Dry Eye Disease.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension for Dry Eye Disease: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Trial.Clinical ophthalmology (Auckland, N.Z.) · 2026Trial
- Effect of Reproxalap Treatment on Dry Eye Disease Symptoms: Analysis of Pooled Data From Two Randomized, Vehicle-Controlled, 12-Week Clinical Trials.Ophthalmology and therapy · 2026Article
- Current and Developing Therapeutics for Dry Eye Disease: Targeting Ion Channels.Current issues in molecular biology · 2026Review
- Special Issue "Cellular and Molecular Insights into Ocular Changes Associated with Systemic Disorders and Conditions".International journal of molecular sciences · 2026Article
- Knowledge, attitudes, and practices towards dry eye disease treatment among patients: a cross-sectional study.BMC public health · 2026Article
- Modulation of corneal sensory processing and pain responses by dry eye and corneal wounding.Frontiers in cellular neuroscience · 2026Article
- Short-Term Changes in Persistent Ocular Discomfort After Add-On Motugivatrep in Patients with Dry Eye Disease: A Retrospective Observational Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Evaluation of the Effects of Eye Drops for Dry Eyes on Neuronal Pain Receptors in a Primary Culture Model of Trigeminal Ganglion Cells.Journal of clinical medicine · 2025Article
- The Exchange Breathing Method for Seizure Intervention: A Historical and Scientific Review of Epilepsy and Its Evolving Therapeutic Paradigms.Journal of personalized medicine · 2025Review
- Corneal Sensory Receptors and Pharmacological Therapies to Modulate Ocular Pain.International journal of molecular sciences · 2025Review
- Topical neurokinin-1 receptor antagonism ameliorates ocular pain and prevents corneal nerve degeneration in an animal model of dry eye disease.Pain reports · 2025Article
- Deciphering mechanical cues in the microenvironment: from non-malignant settings to tumor progression.Biomarker research · 2025Review
- Ion Channels as Potential Drug Targets in Dry Eye Disease and Their Clinical Relevance: A Review.Cells · 2024Review
- Pinning down a perpetrator in postsurgical eye pain.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- TRPV1 corneal neuralgia mutation: Enhanced pH response, bradykinin sensitization, and capsaicin desensitization.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Transient Receptor Potential Vanilloid-1 Channels Facilitate Axonal Degeneration of Corneal Sensory Nerves in Dry Eye.The American journal of pathology · 2024Article
- Thermosensitive TRP Channels Are Functionally Expressed and Influence the Lipogenesis in Human Meibomian Gland Cells.International journal of molecular sciences · 2024Article
- Development of a Probability-Based In Vitro Eye Irritation Screening Platform.Bioengineering (Basel, Switzerland) · 2024Article
- Squishy matters - Corneal mechanobiology in health and disease.Progress in retinal and eye research · 2024Review
- A Novel Quaternary Ammonium N-Propylamiodarone Bromide Provides Long-Lasting Analgesia Against Corneal Pain.Drug design, development and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Dry eye disease (DED) is a multifactorial disorder in which the eyes respond to minor stimuli with abnormal sensations, such as dryness, blurring, foreign body sensation, discomfort, irritation, and pain. Corneal pain, as one of DED's main symptoms, has gained recognition due to its increasing prevalence, morbidity, and the resulting social burden. The cornea is the most innervated tissue in the body, and the maintenance of corneal integrity relies on a rich density of nociceptors, such as polymodal nociceptor neurons, cold thermoreceptor neurons, and mechano-nociceptor neurons. Their sensory responses to different stimulating forces are linked to the specific expression of transient receptor potential (TRP) channels. TRP channels are a group of unique ion channels that play important roles as cellular sensors for various stimuli. These channels are nonselective cation channels with variable Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.